Ladies and gentlemen, thank you for standing by and welcome to the UnitedHealth Group first quarter 2021 earnings conference call. At this time, all participants are in listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]. As a reminder, today's program is being recorded. And now I would like to introduce your host for today's program, Andrew Witty. Please go ahead, sir.

(Audit Start)Good morning and thank you for joining us to discuss our first quarter results and positive outlook as we continue to execute on UnitedHealth Group's long-standing mission and strategies. The exceptional dedication of the people of Optum and UnitedHealthcare again defined this period. They have adapted swiftly and creatively to demand and rapidly changing circumstances, implemented new ideas, and importantly remain focused on serving people exceptionally well. As a result, adjusted earnings per share were $5.31, reflecting strong execution at both UnitedHealthcare and Optum. In light of our strong start to the year, balanced with continued respect for the potential pandemic-related effects we have previously described, we are increasing our full-year adjusted earnings outlook to a range of $18.10 to $18.60 per share. I will touch briefly on two highlights among many in the quarter that illustrate the increased momentum our colleagues at UnitedHealth Group are driving. People served with our employer and individual offerings grew nearly 100,000 in the quarter, even within the context of a challenged U.S. employment environment, and this underscores the growing consumer orientation affordability and breadth of our products. OptumInsight revenues increased 14% and operating income increased 45% compared to the year-ago period as more normal activity levels among healthcare system customers returned leading to expansion in how we help them advance clinical and operational excellence. Significant innovation and automation in the OptumInsight businesses drove strong productivity gains. We have the right capabilities, assets, and strategies in place, and we remain restless to innovate, evolve, and further integrate our offerings to serve more people more effectively, both directly and with our many external partners throughout the healthcare environment. To achieve this, we have been sharpening our focus in three key areas. First, delivering even greater value to those we serve throughout the healthcare system…

Thanks Andrew. As Andrew noted, we continue to drive growth by supporting more affordable, simpler, quality care across Optum and United Healthcare. These are themes you have heard us cover before, and we continue to see the benefits of this approach for the people we serve. Let me turn those themes into some specific examples across Optum and UnitedHealthcare that illustrate how our approach is working. First is how we have been simplifying the consumer experience over the past year. We have driven greater engagement with seniors by increasing adoption of digital tools. Monthly active users of our digital offerings have risen double digit with similar increases in online transactions. This has led to greater adoption of our digital therapeutic offerings. In the first quarter, high-risk chronic disease patients in our home monitoring program logged over 1.5 million biometric measurements such as glucose level, enabling 99% medication compliance and an NPS of 84. (Audit End) We have also made it easier for people to get and maintain behavioral health support by expanding traditional and provider network and combined them with modern digital therapeutic services. Behavioral health needs have increased significantly during the pandemic. And as a result, we have seen substantial adoption in our digital behavioral platform that provides on-demand emotional support, logging a rise of over 100% in utilization. Always accompanying our work to simplify healthcare is Optum and UnitedHealthcare's sharp focus on delivering high-quality care. We have talked to you before about the advances we are making to integrate patient specific health data and plan information directly into the physician's workflow. Clinicians can see gaps in care and act to close them during the patient's visit in addition to other steps that facilitate more efficient care and better outcomes. We now support over eight million of these insight-enabled…

Thank you Dirk. Before I review the performance of our businesses, as in recent quarters I would like to provide an update on the care patterns we are seeing as the pandemic continues to evolve. Over the course of the first quarter, total care activity including COVID-19 related care ran marginally below seasonal baseline. Pacing of elective care activity through the quarter generally track and in opposite directions with the rise and decline of COVID incidence rates which were much higher in the early part of the quarter than in the latter part. To put this in perspective, February and March showed COVID-related care at about half the level experienced in January. Since the quarter's end, we have again began to see a rise in COVID-related care while at this time not approaching the January level. Outpatient care activity was moderately below seasonal baseline for the full quarter, running in counterpoint to the COVID incidence patterns over the three months and reflecting a well below average influenza and respiratory illness season. And total inpatient activity was modestly above seasonal baseline with over 55,000 COVID-19 related admissions during the quarter compared to 65,000 in the fourth quarter of 2020. Moving to business unit performance. OptumHealth's first quarter revenue and earnings increased 35% year-over-year. Revenue per consumer served grew 31% over the year ago quarter. The growth in this metric continues to reflect the expanding number of people served under value-based care arrangements and the increasing acuity of the care services we offer. OptumInsight's revenue grew 14% in the quarter and earnings 45%, due to growth in our services and technology offerings and improved productivity. The revenue backlog at $20.8 billion grew $1.6 billion over the first quarter 2020, as more normalized business activity started to return among our provider and payer…

Thanks John. The story you heard about this quarter is the story you have heard for many years and will continue to do so about UnitedHealth Group, a focus on better serving people and organizations in healthcare using the combined capabilities of Optum and UnitedHealthcare to improve care, cost and experience and an unwavering attention to execute for excellence in all that we do. Operator, let's open it up for questions. One per caller, please.

(Audit Start)Certainly. Our first question comes from the line of Matt Borsch from BMO Capital Markets. Your question, please.

Hi. Yes. Good morning. Congratulations on the quarter. I have a question for you on the prior-year reserve development which is obviously a very large number. Can you just talk to where that emanated from in terms of components, whether by program or by quarter in 2020, and how that may be influencing your posture on forward reserving?

Great. Thanks for the query. I am glad you asked that. I know a lot of people probably have that in mind. John, you should answer that, I think.

Sure. Matt, good morning. It's John Rex.

Good morning.

Let me give a little color on that. So, yes, prior development, $1 billion favorable versus $850 million in the 4Q. As I am sure you would expect, that emanates heavily from the second half of 2020 and a lot from the fourth quarter. It was favorable really across the businesses. The elements there that would be driving that would be largely along care deferral activity that would have occurred in the quarter. I think when you think about impacts to the company and P&L impact, certainly there are significant mitigating factors that I know you are well aware, MLR rebates, risk order arrangements, reserve reestablishment that occurs. When I look at it and take it all together with those mitigating factors, P&L impact would have been in a similar zone to last year's first quarter with those elements coming in. Thank you.

Thanks John. Thanks Matt. Next question, please.

Certainly. Our next question comes from the line of Kevin Fischbeck from Bank of America. Your question, please. Sorry, our next question comes from the line of Robert Jones from Goldman Sachs.

Great. Good morning. Thanks for the question and congrats to Andrew and Brian on the new roles. Actually, I just wanted to ask one on OptumHealth. I think you said 35% of the growth there was driven by global cap. You also shared two million risk patients in OptumCare are now in global cap. Just curious if you could give a little bit more on kind of where you think this number could get to? The number of patients in global cap arrangements within OptumCare this year and then maybe over time, and then it would be helpful to understand a little bit just how many of the 20 million patients you highlighted are actually in MA today? Thanks so much.

Great. Listen, Robert, thanks so much for the question. Before I ask Wyatt Decker to add, you put your finger on a really key part of the growth strategy going forward. Clearly, you are going to see over this year and next year an accelerating move towards more capitated patients within the OptumCare universe. As I mentioned in my prepared comments, there's a tremendous opportunity as we look at those 20 million and growing number of patients who we look after migrating towards what we believe to a better mechanism to help them manage both their care outcome and also the cost implications. So, you will see that continue to accelerate as we expand our OptumCare networks. We are rapidly transitioning our capabilities clinic-by-clinic to be able to do this, and it's one of the areas I think we feel extremely optimistic about future momentum. But to give you a little bit more detail, Dr. Decker, who leads OptumHealth, please?

Yes. Thank you, Robert, for the question. And Andrew, I think you set it up nicely. OptumCare has become the nation's preeminent ambulatory delivery of value-based care. It is physician-led and increasingly you will see us bringing comprehensive services to bear to meet the needs of all of our patients with a particular focus on value base and a particular focus on the fully capitated individual. We will continue to grow over 250,000 lives this year, and you can expect that to accelerate in the years to come as we continue to attract individuals through organic growth as well as through our partnership with UHC, and as Andrew mentioned nearly 90 other providers. Thank you.

Thanks Wyatt. And thanks Robert, for the question. Next question, please.

[Operator Instructions]. Our next question comes from the line of Lisa Gill from JPMorgan.

Hi Lisa. Go ahead.

Good morning and thank you for taking the question. I am just curious how we think about digital and telehealth impacting medical costs? What you have seen thus far? And what's the future role post the pandemic when we think about helping to control costs from a telehealth perspective?

Lisa, that's a great question, I am going to ask in a second Dr. Decker. And also I think will ask Dirk McMahon to make a couple of comments, but let me just preface that. So, we have obviously seen telehealth develop as a set of capabilities over the last several years. We have been a very extensive user of those capabilities, but I think one of the things we have seen from 2020 and the pandemic is really a kind of shift in terms of people's thinking and willingness to utilize telehealth. We also think that the way in which they are being utilized is evolving. And so, what you are going to see from us and it is one of the examples I might cite in terms of the opportunity for new product development between Optum and UnitedHealthcare is, you are going to see UnitedHealth Group lean forward into much more integrated telehealth capabilities. We have got a number of new initiatives in deployment as we speak operating between the two companies. And with that introduction, let me pass it over to Wyatt to maybe give you a little bit more detail on that. And then, I think it would be good to hear from Dirk the perspective he has on this. So, Wyatt first.

Yes. Well, thanks for the question. And as you heard us mention before, we are very proud of how quickly we stood up over 17,000 providers during the pandemic on telehealth solutions, but that really just is the beginning and of course across the country, we have seen a massive shift in consumer adoption and willingness to engage in virtual health solutions as well as with our providers more broadly. (Audit End) So our philosophy is that, not all telehealth is created equally and as we continue to develop our new products, you will see us integrating physical care, virtual care, home care and behavioral care in a way that is innovative and differentiated. And in fact, we have already launched a product we call Optum Virtual Care that is live in all 50 states and is doing just that. And what will really differentiate our product to those that we serve is the ability to offer virtual solutions but then, if necessary, immediately connect them to a live bricks-and-mortar solution for more complex or thorough care as well as identifying and triaging both physical and behavioral health care needs and offering comprehensive behavioral health care. We are seeing continued sustainability of virtual care solutions which as you may know peaked during the height of the pandemic have declined some but are still probably 10x where they were pre-pandemic and certain conditions or behavior or areas like behavioral health care are now seeing about 50% utilization through virtual services. So we are very excited about where we are going to take this. I will turn it over to Dirk.

Yes. Thanks Wyatt. I think Andrew and Wyatt pretty will drained it. But let me say a couple of things. First, we know that people want to meet with their doctor and we have been focused on facilitating that with OptumCare. And people, basically, as you look at how things evolve, the brick-and-mortar physician, that's the vast majority of the tele business today. I would also say that I do see a tremendous opportunity for new models and new products strategies with OptumCare and others where we lean towards those providers who have again the best outcomes and provide the most efficient care. So like any other doctors in our network, we at UnitedHealthcare going to be looking at that strongly and we think OptumCare can provide that very well. That's it. Thanks Lisa.

Thanks Dirk. Thanks Wyatt. I have got to say, Lisa, I have been keeping an eye on the patient verbatims as we have been deploying the Optum Virtual platform that Wyatt referred to and really the feedback is really extraordinary in terms of how patients are seeing this, the benefit they feel from that and the ease with which they are able to engage with it. So this is exactly the kind of thing you are going to see going forward. I think Optum is in an extremely advantaged position being able to bring together this notion of integrated telehealth with physical and behavioral health. And that's going to be the path we go. And I think we are on the verge of kind of next generation of what this looks like versus what we have seen previously. So Lisa, thanks so much for raising the question. And next question, please.

Certainly. Our next question comes from the Kevin Fischbeck from Bank of America. Your question please.

Great. Thanks. I guess one clarification first I guess. Does your guidance assume anything for sequestration delay? But then I guess the real question is, the $1. 80 that you guys are still including in your guidance, it sounds like things are starting off the year relatively well with the overall utilization coming in better and membership growing and some of the OptumInsight things kind of normalizing. I guess, how do you think about that $1.80? How is that progressing? And what kind of signposts you need to kind of see before you feel like that number might come in lower than that?

Yes. Listen, Kevin, thanks for the question. I am going to ask John in a second to refer to the $1.80, the math I guess behind that and the underlying trends. As far as sequestrations comes in, obviously we are keeping a close eye on the guidance from the administration. We have clearly seen the extensions. But the guidance raise we have given today is not caveated by that in anyway. So we have our assumptions on that but the guidance stands not withstanding any outcome there. John, on the $1.80?

Yes. Kevin, it's John Rex. Good morning. Let me talk a little bit about that and how we think about that progressing throughout the course of the year. So a few impacts here. I think the first, the important impact, I suggested that if a significant majority, I would call it, 70% of our projected COVID impact is really occurs in the second half of the year. And just to be frank, we just don't know enough now about what is going to happen later in the year to kind of have a very meaningfully different projection of what our full year results will be in terms of, will it be better in terms of better than the original projections, except for what we have experienced thus far which we expected some stronger underlying business performance growth across the number of businesses. We have executed well on productivity measures. And maybe just very modestly less impact in the 1Q unfavorable impact than we would have anticipated. But the important component there being that is really much more a back half weighted view in terms of COVID-19 impact. That's really premised upon our expectation that as we get later in the year, people are going to be more able to access previously deferred care and at higher acuity levels as a result of missed or postponed treatments. And that's what we have build into that view in terms of an expectation. But that's really unusual time still, no question. And we have therefore increased our full year estimate by what we know today.

Thanks John. And Kevin, thanks so much for asking the question. I mean I think John really summarized it super well. We have raised our expectations for the year based on our experience so far this year and we have retained that $1.80 assumption, if you will, in terms of what could happen. But we obviously don't have the detailed visibility of that yet. But we feel that's the right balanced stance to take in terms of the rest of this year. So I hope that's clear and thanks so much for the question, Kevin. Next question?

Certainly. Our next question comes from the line of Josh Raskin from Nephron Research. Your question, please?

Hi. Thanks. Good morning here with Eric Percher as well. So our question this quarter again on OptumHealth and appreciate the comments in the prepared remarks and the Q&A. But I want to speak to the ultimate strategy around the accumulation of employed physicians. And if this is all about a move to global capitation and we are really more interested in the how, right. Is this more center based like what you are talking about in Riverside, California? Is this more of a technology overlay that enables the physicians to do this? And then I would again, how many of this 20 million, I understand 250,000 will move this year, but how many of those 20 million will ultimately end up in global cap, in your mind?

Josh, thanks for the question. And before I pass it to Wyatt again to respond to the specifics, let me just give you a sense of how we see this play now. And I think the answer to your question is really both. So we absolutely see tremendous opportunity to continue to develop a variety of different clinic types. And if you look at the, I cited one particular example but we have been open in a wide number of different type of clinics depending on the environment over locality that we are operating in. And you should continue to expect to see that degree of customization according to the need of the geography. It's not a one size fits all model, by any means. So you will continue to see that. But at the same time, we strongly believe there is opportunity over the next few years. And this is why I focused in my kind of second there over going deeper around technology. How we can then help those clinics operate more efficiently? How we can ensure they are better connected, both locally with other clinics that we may own or to a high level of information support. So we see this as being a highly activated network of clinics and centers. The center, the network itself will have a high degree of diversity in it because it needs to be responsive to the needs of the locality, the community that we are operating in. And of course, as sensitive to the previous comments, it will have a very significant telehealth capability deployed alongside it. But Wyatt, maybe you could talk a little bit to how you see the progression within the 20 million?

Yes. Thank you Andrew. Thanks Josh. Great question. We will continue to evolve. And one of the pieces that will differentiate us as comprehensive care providers is just that, being comprehensive. And so you will see us continuing to weave together products and services that meet people's needs in new and innovative ways. And telehealth and digital solutions are a big piece but not the only piece. The other part that I would call out is, we are increasingly leveraging technology to bring advanced decision support to our physicians and providers. And you may have heard previously about OptumCare. This is a value-based care delivery set of decision tools that are yielding real results, giving people the best, highest quality care that eliminates what we tend to call low value care and is a differentiator. So we will continue to deploy those technologies. As you know, we are on track to grow by over 10,000 physicians. We are now at 56,000 doctors, both affiliated, contracted and employed and we will leverage all of those models as we go forward and we continue to evolve and employ doctors who are really actually quite attracted to our model of value-based primary care. We eliminate much of the clerical burden in our physicians in advanced practitioners' practice and let them focus on the work they love. So this is really gaining traction among our physician workforce. And then to your point around how much of the 20 million lives that we serve today will ultimately be capitated, we anticipate that not only will a significant portion, you heard the number two million today and 0.25 million as we mentioned growing. So as we continue to grow, we also expect that we will always offer a host of modalities including fee-for-service. And that actually is a feeder system, as we think about value-based care being kind of the core of what we offer and fully capitated, the core of the core, if you will. Thank you.

Thanks Wyatt. And maybe I will just ask Dan Schumacher to briefly add to the comments and talk a little bit about Optum At-Home which is a further dimension of this. So go ahead.

Thanks Andrew. And great question, Josh. To the question around sort of center-based, tech-based, data-enabled and different versions of that that Wyatt was talking about, Optum At-Home is a great example of a collaboration between UnitedHealthcare and Optum that's in relatively early stages. But we focused on Medicare Advantage members that are in dual special needs plans initially. And that's a full risk offering and we are doing it in markets where we don't currently have local OptumCare practices. So what we are doing in the program is really both providing care but also arranging and coordinating care. So we are trying to address medical, behavioral and social needs and the results initially have been great. We have improved access for people with more than 80% having in-home visit and more than half of them getting connected back into office-based care, social services referrals and so forth as well as great health quality and outcome. So today we have got a little under 100,000 lives across six markets. We are looking to expand that across the Medicare Advantage Dual SNP but also into the individual MA we are doing with UnitedHealthcare and ultimately look to do that with other health plans. So another growth vector for us as we look at building out our value-based orientation.

So Josh, I mean I know that was a little bit of a long answer from the three of us, but you asked a really important question. And this is really one of the core elements of the future of the company. And it's why you have heard us talk so much about OptumHealth, OptumCare and you can see the growth potential. We are at that two million life level now. We clearly see the capitation strategy as a highly effective strategy to deliver both quality and cost management for patients. That movement is really significant and it's really moving strongly. And with the development of the diverse sets of clinics and skills, the development of the technology support that you have just heard refer to, we believe we are in a very strong position to be able to be the leader in ability to manage those patients in the best possible way and ensure that they get the kind of health care they deserve. So Josh, thanks so much for asking the question. Next question, please.

Certainly. [Operator Instructions]. Our next question comes from the line of Ricky Goldwasser from Morgan Stanley. Your question, please.

Yes. Hi. Good morning. If we think about the utilization, you gave us some data on how utilization is tracking. But can you give us little bit more details on how it's tracking across the different patient population? And also we talked about acuity levels, your expectations for acuity level to step up second half of the year. But from the experience to-date, as you are starting to see individuals that are coming back, what type of acuity you are seeing for those that haven't received care for the last year? And I think the final one there, if you can just remind us as you think about that guidance for the full year, are you assuming that utilization by year-end is going to be above the 2019 baseline?

So great question, Ricky. I am going to ask Brian Thompson, who has recently been appointed as the Chief Executive Officer of UnitedHealthcare, to respond to that. So, BT?

Yes. Thanks for the question there. When I think about baseline, what I can say right now is, what we are seeing is largely tracking to our expectations. And as we had signaled, where we see abatement in services, it's largely offset by the increase in COVID-related costs. And that's tracked as we had expected. When you back out the impact of some suppressed utilization, the underlying factor is associated with medical cost trends largely look like they did. We aren't seeing significant upticks in services in specific areas out of the norm. So I would say, it looks a lot like utilization prior to the COVID implications. And when I think by line of business, I would say, generally tracking a little below baseline in both our government programs, closer to baseline inside our commercial business. But largely in track with what we had expected. And where it's a little out of line again where perhaps infection rates were higher, we saw that naturally offset with greater utilization. So first quarter, I would say, largely as expected.

John, do you want to add?

Yes. Ricky, good morning. It's John Rex here. So as Brian noted, one of the aspects we look for is this rising acuity from patients that have deferred care or missed treatments. And at this point, we don't have evidence of that occurring. And it could be just that it's still too early on to have enough evidence to see it. But we have not yet seen that rising acuity in the populations that we serve. Your point in terms of how we think about as we get later into the year and why that moves like it does and you heard my commentary that a significant majority of the $1.80 we have layered into the second half of the year. That is largely because of the assumptions around those elements that we see that people are increasingly able to get the care they need, the amount of care deferrals declined meaningfully as you get into that latter part of the year. They are accessing the system. And we do get into these elements where we see rising acuity coming in. So those are the elements that are premised in terms of that expectation at this point. But really and the other element that Brian touched on also just in terms of your populations, you have commercial, a little more access to the system versus the public program members. Thank you.

Thanks John. And thanks, Ricky, for the question. Next question, please.

Certainly. Our next question comes from the line of Dave Windley from Jefferies. Your question, please.

Thank you. Good morning. Thanks for taking my question. I want to ask a question about integration and longitudinal care and data versus fragmentation. And the question is this. So Andrew, over many years, Optum has really invested a lot of money in kind of aggregating data about the patient status, care and services delivered, so that touchpoints with United or Optum could have all that information at hand. I guess what I am interested in around kind of your build-out but specifically the comments you have made about telemedicine is, how important is it for telemedicine to enhance and augment the longitudinal and integrated nature of care versus fragmenting that by having it kind of siloed as a separate benefit? Thanks.

Right. It's a great question. So I think our bias is increasingly and I think rightly toward driving a more and more seamless, simple, easy to access care environment, both for the patient and the provider actually. So what that speaks to is, trying to avoid the fragmentation of the interface and definitely trying to avoid the fragmentation of the information that then sits behind it. So we want to really try and create much more seamless opportunity. So for example, I would give you a real example in Optum Virtual which is, you have heard a little bit on the call already today. So of course, patients are looking for a way to engage with the physician. They actually want to talk to their physician. So one of the things that we are doing is building that platform. But then there might be situations where the physician wants to bring in a specialist into that conversation. Now in a multi-disciplinary clinic, they might be in a position in normal times to go down the hall, get somebody to come down and visit. Now in Optum Virtual, they are able to do that kind of thing. So that's an example of trying to bring that integration, even within the virtual space. So it kind of replicates a little bit more what you might expect in a physical environment. And so, we definitely see the need to try and drive toward that. And we definitely want to try and create the fluidity of the information to ensure that physicians have what they need when they are in front of the patient, when they are talking to the patient so they can make the best possible choices. So we want them to be as highly educated as possible in that context. So we are leaning very much towards the idea of integrated seamless and that's true whether you are in the physical or the virtual space and we want the two to sit together. Thanks for the question.

Yes. Thank you.

Next question. Thank you.

Certainly. Our next question comes from the line of Justin Lake from Wolfe Research. Your question, please.

Thanks. Good morning. A lot of good topics already covered here. So I just have a few quick follow-ups. First, the detail on OptumCare was very, very helpful. I was hoping I could ask for one more piece of information here which is, so it sounds like you are going to have 18 million people out of 20 million that are still not capitated. Wondering how many of these are sitting in Medicare Advantage plans that aren't capitated, given this is where most of the capitation happens? Just trying to think about the potential kind of pent-up growth there. And then on Medicare Advantage, it sounded like your health assessments are going better in 2021. Should we expect that you should get a significant amount of that risk or headwind that everybody saw for 2021 to reverse next year and get those revenues back? And then lastly, could you give us an update on earning seasonality for the year versus a 50/50 split you talked about on the last update? Thanks.

Hi Justin. Thanks so much for the questions. I am going to ask in a second, John to talk to the earning seasonality and for Wyatt to address the degree to the population we have within the MA plan. Let me just touch on the health assessment. You heard in the prepared comments the very strong performance of the HouseCalls program, actually higher than last year, record quarter actually in terms of performance at HouseCalls. And you are quite right, that makes us feel pretty optimistic that that headwind that we saw is going to dissipate pretty rapidly as we rotate into 2022. And that gives us kind of a rise in optimism that much of that kind of the negative headwind that characterizes the emergence of the pandemic starts to mitigate at least on that dimension. Obviously, we don't know what's going to happen in the next few months with this disease. But as we sit here today, that would be the right kind of expectation to look at. Let me go to Wyatt first. And then John, if you pick up from Wyatt on the seasonality. So, Wyatt?

Yes. Justin, thanks for the question. And of the individuals that we serve that are not in fully capitated programs, about a third of them are seniors. And so you can think of that as the Medicare population that we serve through a variety of touchpoints in our care delivery assets. And then as you would expect, a subset of those are already in MA plan, which is to your question. And so, we see, again, a great potential to continue to capture and enroll and care for MA patients through OptumCare's delivery capabilities. And you will also see us going deeper in the markets that we are in and bringing our very mature risk-based platform in established markets to new markets where today we are primarily fee-for-service. So expect both geographic growth and increasing depth and penetration in the markets we serve today. Thank you.

Justin, good morning. This is John. In terms of the seasonality, so historically we have been at, what I would call, a kind of 48/52 split in terms of first half, second half. I would put that probably more in the zone of first half being in the 52, 53 zone this year. That is really due to how we are tracking in the $1.80 per share impact on it that the majority of that is occurring in the second half of the year. So that would be really the reason for the seasonality looking different this year than it has looked in other years. Thanks.

Thanks John. And thanks, Justin, for the questions. I appreciate it. We just have time for two more questions, operator. So let's go to the next one.

Certainly. Our next question comes from the line of A.J. Rice from Credit Suisse. Your question, please?

Hi everybody. Maybe drill down a little bit on OptumInsight. Obviously, it had a really good margin trend this quarter. I wondered, because I know there was discussion last year during the pandemic that some of the John Muir type of deals were somewhat on hold as it was tough to sell a health system on that, given social distancing and so forth. Since the fact that you don't have investments for those, is that helping you on the margin right now? And are those now basically reopened that you can go out and bid? And maybe another aspect of the OptumInsight story, as you think ahead now to Change Health coming on board, should we assume that there is a pause in selling activity of some sort while you integrate that and position the company to be even stronger and that business to be even stronger? Or I know there's a lot of synergy assumed to be coming online with that? So how should we think about how Change Health coming online affects the trajectory of that business?

Hi A.J., thanks so much for the question. I am going to ask Robert Musslewhite to make some comments in a second around the progression of the margin in the quarter, which obviously we are very, very pleased to see that. And it was due to a ton of hard work on a number of different dimensions that Robert can describe to you. Just on those large contract agreements, like the one we have with John Muir. Yes, there was a bit of disruption last year. But I would say that is absolutely back on stream now in terms of a line of business for us. And we have a very, very exciting pipeline. And that pipeline exists both in the short, medium and longer term. So that's an area you are going to hear more from us on and is absolutely back in full swing. In terms of Change, obviously we are very keen to continue to work through the regulatory process. We expect this to close in the second half as we have previously indicated. And you should not expect any disruption from us bringing Change onboard to really anything that we are doing and especially not in terms of our selling activity. So we absolutely continue to operate OptumInsight fully as if we were not in a transaction. And even post-transaction, I would fully expect the ongoing sales energy of the company to be not disrupted. So nothing. I really would not lead you to expect anything on that front. With that, Robert, would you go into a bit more detail, please, around the evolution of the margin during the last quarter?

Sure. And hi A.J. Listen, we are pleased with the quarter. It was a really good quarter on the topline and that of course profitable growth that contributed to margin. But specifically on margin, we also are really seeing the results of a lot of the modernization work we did across 2020. So last year, we undertook a significant review of the business across the operations and drove to find some multiple ways to drive stronger and more efficient performance and help ensure that the investments we are making were invested appropriately against our key growth opportunities. And so if you look at those initiatives, multiple automation initiatives using advanced techniques in AI, MLP, machine learning, it really drove a lot of short-term productivity. But it also drives a situation where we feel like we have made sustainable margin improvements for the longer term. And that puts us in a position to be more competitive. And that actually rolls over to exactly what you are mentioning, being more competitive on the large engagements. And as Andrew said, we feel really optimistic about that pipeline and where it's headed. The disruption was more in timing and not really an interest during the pandemic. In fact, during the pandemic, I think there was growing recognition among our health system relationships that this was a very productive way to work with Optum and a really important need for them as they face some disruption even coming out of the pandemic to their finances in ways that we can sustainably support them in a really holistic way. So we feel like that's a great path forward. We are excited about the business and feel like we have made some important changes that put us on a really good track going forward.

Thanks Robert. And A.J., thanks for asking the question. And Insight, I think, is really on the cusp of a very exciting few years, thanks to the significant work that was done last year, the increasing rate of opportunity that we see to bring in new significant contracts and then obviously the pending Change acquisition creates some really exciting momentum for this business. So this is an area I fully anticipate us looking to for material growth going forward. Operator, last question, please?

Certainly. Our final question comes from the line of George Hill from Deutsche. Your question, please.

Hi. Good morning guys. And thanks for squeezing me in at the end. Andrew, I would just be interested to hear your commentary about the outlook for commercial bundles. I know we are all talking a lot about risk-sharing and what I call risk syndication in the Medicare Advantage space and the bundling of risk in the Medicare Advantage space. But I would be interested in the company's outlook for the commercial business and if you are seeing increased uptake of kind of more risk-sharing tools in that market? Thank you.

Yes. Great. So listen, I think in the commercial space and I am going to ask Bill Golden to come in here real quick. But I think in the commercial space, it's just as possible for us to start to design innovative products and we have already begun to do that between Optum and UHC. Let me ask Bill to dive into that in a little bit more detail. Bill?

Yes. Thank you. And thanks for the question. Yes, I would say, we are in the early stages of provider-aligned products where we are taking advantage of that risk base. As an example, in our Southern California OptumCare partnership, Harmony really continues to be a cornerstone of those offerings. We are learning a lot with that product, not only regarding how it's priced, but more importantly the actual experience for the members. And so we are using that as a cornerstone and as a program to continue to roll out throughout the country with other areas. So we are very optimistic about the opportunities that that will show in the future. But still in the very early stages of our global cap with the commercial business. Thank you.

Thanks Bill. And George, thanks so much for the question. That's clearly an area we expect to see more in the future. But as Bill says, it's early days and we will see how that progresses. With that, everybody, thank you so much for spending the time with us this morning. As we move through what we all hope are the latter stages of this pandemic, you can expect us to continue to focus on the areas where UnitedHealth Group can do the most to improve healthcare, including adding even greater value at the intersection of Optum and UnitedHealthcare, applying our technology and expertise to create a better functioning, more responsive and cost-efficient healthcare system and making healthcare work better for consumers. We look forward to connecting with you again on these priorities in the weeks and months ahead. And once again, thank you for your attention this morning. Bye, bye.

Thank you, ladies and gentleman, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day.